Consideration for treatment of bisphosphonate-related osteonecrosis of the jaw.
10.5125/jkaoms.2010.36.3.206
- Author:
Kyung Ha YOU
1
;
Kyu Ho YOON
;
Jung Ho BAE
;
Jae An PARK
;
Gun Chan PARK
;
Jae Myung SHIN
;
Jee Seon BAIK
;
Jeong Kwon CHEONG
Author Information
1. Department of Oral and Maxillofacial Surgery, Inje University Sanggye Paik Hospital, Seoul, Korea. dentpd@paik.ac.kr
- Publication Type:Original Article
- Keywords:
Bisphosphonate;
Osteonecrosis;
Osteoporosis
- MeSH:
Bisphosphonate-Associated Osteonecrosis of the Jaw;
Diphosphonates;
Humans;
Hypercalcemia;
Osteonecrosis;
Osteoporosis
- From:Journal of the Korean Association of Oral and Maxillofacial Surgeons
2010;36(3):206-210
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
Bisphosphonates are widely used to treat osteoporosis, hypercalcemia of malignant tumor. Despite their clinical benefit, bisphosphonate-related osteonecrosis of the jaw (BRONJ) is a newly documented complication to patients receiving these drugs and first recognized by Marx in 2003. Thus, consideration of prevention and needs regarding unequivocal treatment regimen have emerged. Recently, several authors emphasized reports on appropriate clinical availability of surgical approach. It serves to concern about guideline for surgical and conservative treatment modalities. So, it is the purpose of this paper to review the current literatures about treatment regimens of BRONJ.
